UB Paderborn / Katalog / Suche / in CDI

Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa

British journal of ophthalmology, 2020-09, Vol.104 (9), p.1203

2020

Link zum Volltext

Verfügbarkeit prüfen

Baseline Visual Field Findings in the RUSH2A Study: Associated Factors and Correlation With Other Measures of Disease Severity

American journal of ophthalmology, 2020-11, Vol.219, p.87-100

2020

Link zum Volltext

Verfügbarkeit prüfen

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

Blood cancer journal (New York), 2021-05, Vol.11 (5), p.103-103, Article 103

2021

Link zum Volltext

Verfügbarkeit prüfen

Partial recovery of visual function in a blind patient after optogenetic therapy

Nature Medicine, 2021-07, Vol.27 (7), p.1223-1229

2021

Link zum Volltext

Verfügbarkeit prüfen

Progression of Retinopathy Secondary to Maternally Inherited Diabetes and Deafness – Evaluation of Predicting Parameters

American journal of ophthalmology, 2020-05, Vol.213, p.134-144

2020

Link zum Volltext

Verfügbarkeit prüfen

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Ophthalmology and therapy, 2020-12, Vol.9 (4), p.889-911

2020

Link zum Volltext

Verfügbarkeit prüfen

Paracentral acute middle maculopathy following COVID-19

Arquivos brasileiros de oftalmologia, 2023-07, Vol.86 (4), p.397-399

2023

Link zum Volltext

Verfügbarkeit prüfen

Binocular Inhibition of Reading in Macular Telangiectasia Type 2

Investigative ophthalmology & visual science, 2019-09, Vol.60 (12), p.3835-3841

2019

Link zum Volltext

Verfügbarkeit prüfen

Macular pigment parameters in patients with macular telangiectasia (MacTel) and normal subjects: implications of a novel analysis

Investigative ophthalmology & visual science, 2012-09, Vol.53 (10), p.6568-6575

2012

Link zum Volltext

Verfügbarkeit prüfen

ELECTROPHYSIOLOGICAL CHARACTERIZATION OF MACULAR TELANGIECTASIA TYPE 2 AND STRUCTURE-FUNCTION CORRELATION

Retina (Philadelphia, Pa.), 2018-01, Vol.38 Suppl 1, p.S33

2018

Link zum Volltext

Verfügbarkeit prüfen

A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3

Archives of ophthalmology (1960), 2012-08, Vol.130 (8), p.972

2012

Link zum Volltext

Verfügbarkeit prüfen

Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT study (report 4)

PloS one, 2013-08, Vol.8 (8), p.e72755

2013

Link zum Volltext

Verfügbarkeit prüfen

High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis

Blood cancer journal (New York), 2022-09, Vol.12 (9), p.128-128, Article 128

2022

Link zum Volltext

Verfügbarkeit prüfen

Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial

Ophthalmology and therapy, 2020-09, Vol.9 (3), p.563-576

2020

Link zum Volltext

Verfügbarkeit prüfen

Correction: Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4)

PloS one, 2013-09, Vol.8 (9)

2013

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Ophthalmology and therapy, 2020-09, Vol.9 (4), p.913-915

2020

Link zum Volltext

Verfügbarkeit prüfen

Repeatability of retinal thickness and volume metrics in neovascular age-related macular degeneration using the Topcon 3DOCT-1000

Indian journal of ophthalmology, 2014-09, Vol.62 (9), p.941-948

2014

Link zum Volltext

Verfügbarkeit prüfen

Revisiting NICE guidelines for initiation of intravitreal anti-VEGF therapy for centre-involving diabetic macular oedema: a survey of current interpretation in the United Kingdom

Eye (London), 2022-09, Vol.36 (9), p.1832-1834

2022

Link zum Volltext

Verfügbarkeit prüfen

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma

Journal of the advanced practitioner in oncology, 2023-09, Vol.14 (6), p.503-518

2023

Link zum Volltext

Verfügbarkeit prüfen

Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial

Haematologica (Roma), 2020-05, Vol.105 (5), p.e261-e263

2020

Link zum Volltext

Verfügbarkeit prüfen

Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8033-8033

2021

Link zum Volltext

Verfügbarkeit prüfen

OAB-049: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)–related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2022-08, Vol.22, p.S30

2022

Link zum Volltext

Verfügbarkeit prüfen

Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Blood, 2020-11, Vol.136 (Supplement 1), p.26-27

2020

Link zum Volltext

Verfügbarkeit prüfen

DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood, 2020-11, Vol.136 (Supplement 1), p.27-28

2020

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa

Baseline Visual Field Findings in the RUSH2A Study: Associated Factors and Correlation With Other Measures of Disease Severity

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Partial recovery of visual function in a blind patient after optogenetic therapy

Progression of Retinopathy Secondary to Maternally Inherited Diabetes and Deafness – Evaluation of Predicting Parameters

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Paracentral acute middle maculopathy following COVID-19

Binocular Inhibition of Reading in Macular Telangiectasia Type 2

Macular pigment parameters in patients with macular telangiectasia (MacTel) and normal subjects: implications of a novel analysis

ELECTROPHYSIOLOGICAL CHARACTERIZATION OF MACULAR TELANGIECTASIA TYPE 2 AND STRUCTURE-FUNCTION CORRELATION

A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3

Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT study (report 4)

High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis

Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial

Correction: Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4)

Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Repeatability of retinal thickness and volume metrics in neovascular age-related macular degeneration using the Topcon 3DOCT-1000

Revisiting NICE guidelines for initiation of intravitreal anti-VEGF therapy for centre-involving diabetic macular oedema: a survey of current interpretation in the United Kingdom

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma

Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial

Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf)

OAB-049: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)–related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)

Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Suchergebnisse filtern